BCL2 and B-cell chronic lymphocytic leukemia: Furthermore, our study revealed that Venetoclax, a BCL2 inhibitor, approved by FDA for chronic lymphocytic leukemia, inhibited stellate cell proliferation and activation in vitro and impeded liver fibrosis in miR-122 knockout mice.